uniQure NV (NASDAQ:QURE) saw unusually-high trading volume on Monday . Approximately 266,372 shares were traded during trading, an increase of 5% from the previous session’s volume of 253,639 shares.The stock last traded at $9.19 and had previously closed at $8.58.

QURE has been the topic of several recent analyst reports. WallachBeth Capital cut their price objective on shares of uniQure NV from $60.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, June 15th. Cowen and Company reissued a “buy” rating on shares of uniQure NV in a research report on Tuesday, June 14th. Leerink Swann reissued a “buy” rating on shares of uniQure NV in a research report on Sunday, June 12th. Piper Jaffray Cos. reissued a “buy” rating on shares of uniQure NV in a research report on Monday, June 13th. Finally, Jefferies Group reissued a “buy” rating on shares of uniQure NV in a research report on Tuesday, May 31st. One equities research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $29.10.

The stock’s 50 day moving average is $7.69 and its 200 day moving average is $11.67. The stock’s market capitalization is $230.57 million.

uniQure NV (NASDAQ:QURE) last issued its earnings results on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing analysts’ consensus estimates of ($0.82) by $0.10. On average, analysts forecast that uniQure NV will post ($3.45) EPS for the current fiscal year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.